Peter Greenberg
Academic Appointments
- Professor Emeritus, Medicine - Hematology
- Emeritus Faculty, Acad Council, Medicine - Hematology
- Member, Bio-X
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Hematology Clinic 875 Blake Wilbur Dr Clinic C MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 498-5030
- Academic Offices
Personal Information Email Tel (650) 725-8355Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Hematology
- Myelodysplastic Syndromes
Administrative Appointments
- Director, Stanford MDS Center (1998 - 2011)
- Head, Hematology Section, VA Palo Alto Health Care System (1979 - 2005)
- Acting Chief, Medical Service, VA Palo Alto Health Care System (1978 - 1979)
Honors and Awards
- International Prize for outstanding research in myelodysplastic syndromes (MDS), J.P. McCarthy Foundation (1997)
Professional Education
| Fellowship: | Stanford University School of Medicine CA (1971) |
| Residency: | Barnes Hospital MO (1965) |
| Residency: | Stanford University School of Medicine CA (1968) |
| Board Certification: | Hematology, American Board of Internal Medicine (1976) |
| Board Certification: | Internal Medicine, American Board of Internal Medicine (1970) |
| Internship: | Barnes Hospital MO (1964) |
Community and International Work
- Chair, Committee on International Outreach, 1998-2001, International&suffix=physician
Internet Links
Scientific Focus
Current Research Interests
The major direction of research in my laboratory is to determine the role and mechanisms of hemopoietic dysregulation in human myeloid malignancies. The relation between molecular changes and cellular phenotype / pathophysiology is being explored using microarray and next generation technologies to evaluate differential gene expression profiles of MDS and AML marrow cells. The impact of cytokines and biologic response modifiers on these molecular features and hemopoietic response is being examined in clinical investigations with MDS and AML patients in therapeutic clinical trials with these agents.
Clinical Trials
- Not Recruiting To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS.
- Recruiting Study of KB004 in Subjects With Hematologic Malignancies
- Recruiting Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
- Not Recruiting A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia
- Not Recruiting Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents
Publications
- Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A. 2013; (8): 3011-6
- Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. J Clin Oncol. 2013; (5): 592-8
- Distinctive contact between CD34+ hematopoietic progenitors and CXCL12+ CD271+ mesenchymal stromal cells in benign and myelodysplastic bone marrow Lab Investigation. 2012: 1330-1341
- Molecular and genetic features of myelodysplastic syndromes. Int J Lab Hematol. 2012; (3): 215-22
- Personal omics profiling reveals dynamic molecular and medical phenotypes. Cell. 2012; (6): 1293-307
- Reduced rRNA expression and increased rDNA promoter methylation in CD34+ cells of patients with myelodysplastic syndromes. Blood. 2012; (24): 4812-8
Help
Trial Administration